מזומן למניה Silo Pharma Inc. (SILO)

Prospects for psilocybin fibromyalgia treatment programs are driving future growth, while speculative risks are already priced in. Changes in cash per share demonstrate liquidity, where the current status equals 3.98. Geopolitical tensions complicate component procurement and patent protection, while strict government control over the transport of neuropsychiatric agents increases logistics costs for Silo Pharma, Inc. (SILO).
פילוחי מדדים מקיפים ואנליטיקה עבור silopharma.com (SILO)

For Silo Pharma, Inc. (SILO), which develops innovative drugs, the level of liquid assets per share on the GURU.Markets platform serves as an indicator of financial viability. This metric is calculated by dividing total cash holdings by the number of shares outstanding, determining the available capital per unit of ownership. In the absence of revenue, this figure demonstrates the burn rate of reserves. A decline in these values signals the issuer's growing dependence on new external investments.